Advanced Enzyme Technologies Ltd · NSE:ADVENZYMES

Advanced Enzyme Technologies — Investor Presentation (November 2016)

38 slides from Advanced Enzyme Technologies's investor presentation, November 2016

  1. Slide 1: Where Enzyme is Life – Investor Presentation

    Where ENZYME is life INVESTOR PRESENTATION NOVEMBER 2016

  2. Slide 2: Disclaimer

    Disclaimer This presentation is for information purposes only and does not constitute, nor should be regarded as, an offer, invitation, inducement, solicitation or advertisement with respect to the purchase or sale of any security of Advanced Enzymes Technologies Limited (“AETL” or “Company”) and no

  3. Slide 3: Table of Contents

    Table of Contents Company Overview 4 Global Enzyme Market 12 Advanced Enzymes - A Unique Investment Case 15 Financial Overview 29 3

  4. Slide 4: Company Overview

    Company Overview 4 Company Overview Global Enzyme Market Advanced Enzymes- A Unique Investment Case Financial Overview

  5. Slide 5: Company Overview

    Company Overview Mission Company Overview It is our mission to see that every human being is able to take advantage of the power of enzymes for well-being and leading a healthy life! Enzymes are specific and Advanced Enzymes is a research driven company catalyse a wide variety of reactions and have

  6. Slide 6: Board of Directors

    Board of Directors Mr. Kedar Desai Mr. Ramesh Mehta Mrs. Rupa Vora Chairman and Independent Director Independent Director Independent Director Mr. Kedar Jagdish Desai, is the Chairman of Mr. Ramesh Thakorlal Mehta is a Non- Mrs. Rupa Rajul Vora, is a Non-Executive our Company and a Non-Executive and

  7. Slide 7: Management Team

    Management Team A double graduate, Piyush first completed his Bachelors in Maths from Mumbai University and then in Finance from Michigan Tech University, USA. Subsequently he completed his MBA from SCMHRD and joined Advanced Enzymes in April 2005. In 2007 and in 2010, Piyush took charge of the Huma

  8. Slide 8: Advanced Enzyme Technologies Limited – A Global Enzyme Player

    Advanced Enzyme Technologies Limited – A Global Enzyme Player Indian enzyme company 60 Developed Indigenous Enzymes Highest market share in India 400+ Proprietary Enzymes Products Amongst Top 15 Global Enzyme Companies 700+ Customers worldwide 6 Manufacturing Units 4 R&D Units 4 India 3 India 50 Pre

  9. Slide 9: Catering to Diverse end-use Industries

    Catering to Diverse end-use Industries ~88% of Total Revenue in FY16 Human Healthcare Animal • Supply enzyme products, & Nutrition Nutrition enzyme blends & customised enzyme solutions • Leverage R&D to deliver high quality products at globally competitive prices Leather Dairy & Cheese Processing Bi

  10. Slide 10: Corporate Structure

    Corporate Structure Advanced Enzyme Technologies Ltd. (AETL) 60%(1) 100%(2) 100% Advanced Advanced Advanced Bio-Agro EnzyTech Enzymes Tech Ltd Solutions Ltd USA  Animal Feed Products  Eco friendly solutions  Agro products  Non-food industries  Focus on South Asia  South-East Asia 100% 100% 100

  11. Slide 11: Brief History and Evolution

    Brief History and Evolution Equity investment by Kotak Private Equity* R&D centres Incorporated (Thane and Takeover of as Advanced Sinnar) Advance Biochemicals recognized Supplementary Pvt Ltd by DSIR Technology 1989 1994 2001 2011 2012 2016 First Takeover of Came up fermentation Cal-India with IPO

  12. Slide 12: Global Enzyme Market

    Global Enzyme Market 12 Company Overview Global Enzyme Market Advanced Enzymes- A Unique Investment Case Financial Overview

  13. Slide 13: Global Enzyme Market: Broad-based Growth led by Specialty Enzymes

    Global Enzyme Market : Broad-based Growth led by Specialty Enzymes Enzymes Usage of Enzymes Global Market Size  Enzymes are natural protein Enzymes molecules USD 9.5 bn 2022  Produced by all living organisms Industrial Enzymes Specialty Enzymes CAGR: USD 7.0 bn 6.5%  Function as specialized High

  14. Slide 14: Underlying Trends Driving Global Enzyme Demand

    Underlying Trends Driving Global Enzyme Demand Growing Population Per capita Income, growing middle class and urbanization, particularly in rapidly developing economies Global Industrial Enzymes (USD Cleaning Food & Animal Other  Expansion of middle class population & meat consumption Biofuel Mn) P

  15. Slide 15: Advanced Enzymes - A Unique Investment Case

    Advanced Enzymes - A Unique Investment Case 15 Company Overview Global Enzyme Market Advanced Enzymes- A Unique Investment Case Financial Overview

  16. Slide 16: What Makes AETL a Unique Investment Case

    What Makes AETL a Unique Investment Case Integrated Strong R&D, Diversified Dedicated and Strong Enzyme Enzyme global Experienced Financial Company with Development & operations Management Performance presence across Manufacturing with strong US Team & Stable Cash enzyme value Capabilities focus Flo

  17. Slide 17: AETL - An Integrated Enzyme Company

    AETL - An Integrated Enzyme Company Diversified  Products catering to various user industries- presence in healthcare & nutrition and bio- processing verticals Product Portfolio Across Verticals  Diversified client base serving 700 customers worldwide  Covering the entire gamut of activities - R&

  18. Slide 18: Diversified Product Portfolio Across Verticals

    Diversified Product Portfolio Across Verticals 88% 12% FY2016 Revenue: FY 2016 Revenue: INR 2,574 mn INR 364 mn Healthcare & Nutrition Bio-processing Human healthcare Animal Food Non-food & Nutrition Nutrition processing processing  Used by  Enables animals  Helps customers to  Improve efficienc

  19. Slide 19: Presence Across The Enzyme Value Chain

    Presence Across The Enzyme Value Chain R&D Commercial Scale Marketing & Continuously Manufacturing Distribution innovating & Flexible & multi Consistent track upgrading product purpose in nature, record & wide offerings allows & capable of product portfolio helps customers meet customizing & leads t

  20. Slide 20: Specialized Business Model With High Entry Barriers

    Specialized Business Model With High Entry Barriers Innovation & Diverse Product Technocrat Product Manufacturing Range & Promoters Development Customer Base Extensive knowledge Specialized Products are Cumulative & expertise of knowledge of effectively increasing experience of enzymes & micro- micr

  21. Slide 21: Strong R&D, Enzyme Development & Manufacturing Capabilities

    Strong R&D, Enzyme Development & Manufacturing Capabilities R&D facilities with Flexible and multi- qualified and purpose manufacturing experienced team facilities  Focus on core competencies  High quality standards conforming to international  Focus on quality accreditations  Intellectual prope

  22. Slide 22: Strong Research and Development Capabilities Enhancing Product Portfolio

    Strong Research and Development Capabilities Enhancing Product Portfolio Thane, Sinnar, Thane, Chino, Maharashtra Maharashtra Maharashtra California Proteomics & Applied Process Development Application Laboratory Services Microbiology & Optimization Development  Purification &  Upscaling  Develop

  23. Slide 23: Strategic Advantage With Extensive Manufacturing Base

    Strategic Advantage With Extensive Manufacturing Base Flexible & Multipurpose facility with aggregate Key Accreditations fermentation capacity of 360 m3 Country Facility Capabilities Capacity Significance ISO WHO GMP+ 22000: Fermentation, cGMP Nashik – 1st fermentation 2005 Recovery & 120 m3 Unit I

  24. Slide 24: Diversified Global Operation & Customer Base

    Diversified Global Operation & Customer Base 55+ 3.6% 1.2%  Geographically diversified revenue base: 63.6% International Operations • Sales & Marketing Team  Diversified customer base: 36.4% Top 10 accounting for 42% of • Domestic & 54.9% revenue* International Markets  700 customers across 50 co

  25. Slide 25: Well Positioned To Grow in the US Market

    Well Positioned To Grow in the US Market through a well established base U.S. Market Remains a Key Focus Area Launched Own Branded Enzymes  Strategically important business -  Marketed to Healthcare professionals sizeable operations in U.S. through & Consumers subsidiaries  Multiple Channel Distr

  26. Slide 26: Strong Financial Performance

    Strong Financial Performance 47.1% Revenue from Operations EBIDTA & EBIDTA Margin (%) 1,382 2,938 43.3% 40.8% 40.6% 36.3% 2,395 1,038 2,204 2,231 896 910 1,717 623 FY 12 FY 13 FY 14 FY 15 FY 16 FY 12 FY 13 FY 14 FY 15 FY 16 CAGR=14.4% CAGR=22.1% 1000 PAT & PAT Margin (%) 30.00% ROE (%) & ROCE (%) 26

  27. Slide 27: Strong Financial Performance

    Strong Financial Performance Net Working Capital (Days) Net Operating Cash Flow 128 1,027 110 110 112 92 486 530 411 451 FY 12 FY 13 FY 14 FY 15 FY 16 FY 12 FY 13 FY 14 FY 15 FY 16 Net Working Capital (Days) Net Operating Cash Flow Net Debt to Equity (x) Capital Expenditure 2.1 344 1.1 1 151 133 0.5

  28. Slide 28: Key Strategies for Sustainable Future Growth

    Key Strategies for Sustainable Future Growth Continued Broaden & Deepen Investment in R&D Geographical Presence • Identify product gaps & • Deepen presence and increase develop new products market share in North America in Healthcare & • Position as an end-to-end enzyme Nutrition and Bio- & enzyme s

  29. Slide 29: Financial Overview

    Financial Overview 29 Company Overview Global Enzyme Market Advanced Enzymes- A Unique Investment Case Financial Overview

  30. Slide 30: Profit & Loss (Standalone) – Q2FY17

    Profit & Loss (Standalone) – Q2FY17 ` in Million except per share data Q2FY17 Q1FY17 Q2FY16 H1FY17* H1FY16 FY16 Particulars Unaudited Unaudited Unaudited Unaudited Unaudited Audited Income from Operations 412.01 373.35 361.25 785.36 669.99 1,391.41 Expenses 296.52 320.17 321.22 616.67 564.96 1,102.0

  31. Slide 31: Balance Sheet (Standalone) - Q2FY17

    Balance Sheet (Standalone) - Q2FY17 ` in Million Particulars H1FY17 FY16 EQUITY AND LIABILITIES Share capital 223.26 217.66 Reserves and surplus 2,120.03 1,524.35 Long-term borrowings 135.24 156.01 Other - Non-current liabilities 167.76 159.34 Short-term borrowings 70.45 294.52 Trade payables 111.05

  32. Slide 32: Profit & Loss (Consolidated) – Q2FY17

    Profit & Loss (Consolidated) – Q2FY17 ` in Million except per share data Q2FY17 Q1FY17 Q2FY16 H1FY17* H1FY16 FY16 Particulars Unaudited Unaudited Unaudited Unaudited Unaudited Audited Income from Operations 908.03 944.98 704.68 1,853.01 1,388.59 2,937.62 Expenses 453.75 468.30 448.27 922.05 836.63 1

  33. Slide 33: Balance Sheet (Consolidated) – Q2FY17

    Balance Sheet (Consolidated) – Q2FY17 ` in Million Particulars H1FY17 FY16 EQUITY AND LIABILITIES Share capital 223.26 217.66 Reserves and surplus 4,104.37 2,563.20 Minority interest 62.95 53.51 Long-term borrowings 138.44 387.52 Other - Non-current liabilities 186.07 175.63 Short-term borrowings 72

  34. Slide 34: Consolidated Balance Sheet

    Consolidated Balance Sheet As at March 31, All figures in ` mn 2012 2013 2014 2015 2016 Equity and Liabilities Shareholder’s Funds 960 1,619 1,664 2,101 2,787 Minority interest 16 24 36 45 54 Long-term borrowings 1,393 1,167 875 540 388 Short-term borrowings 360 337 391 236 296 Trade payables 182 16

  35. Slide 35: Consolidated Profit & Loss Statement

    Consolidated Profit & Loss Statement For the year ended March 31, All figures in ` mn 2012 2013 2014 2015 2016 Revenue from operations 1,717 2,204 2,395 2,231 2,938 Other income 31 36 10 10 9 Cost of materials consumed 478 511 471 477 590 Gross Profit 1,239 1,693 1,924 1,754 2,347 Gross Profit Margi

  36. Slide 36: Consolidated Cash Flow Statement

    Consolidated Cash Flow Statement For the year ended March 31, All figures in ` mn 2012 2013 2014 2015 2016 Profit before tax 477 760 278 738 1,225 Adjustments for non-cash transactions 57 79 128 97 87 Interest expenses 117 90 89 80 67 Changes in working capital (32) (258) 155 (115) (77) Income taxes

  37. Slide 37: Shareholder Information

    Shareholder Information Stock Data (As on 11 November 2016) Top Institutional Holders Institutions OS (%) Market Capitalization 42,755.4mn Motilal Oswal Most Focused Multicap 35 1.43 Fund Shares Outstanding 22.3mn Reliance Capital Trustee Co. Ltd-A/C Reliance 1.35 small Cap Fund Free Float (%) 6.5mn

  38. Slide 38: Thank You

    Thank You Advanced Enzymes 5th Floor, 'A' wing, Sun Magnetica LIC Service Road, Louiswadi Thane (W) 400 604, India Tel: +91-22-4170 3200 Fax: + 91-22-25835159

Advanced Enzyme Technologies — Investor Presentation (November 2016) on 6ix